Optimal medical management of heart failure (HF) improves quality of life, decreases
mortality, and decreases hospitalizations. Cost may contribute to suboptimal adherence to …

Cardiovascular disease holds the position of being the foremost cause of death worldwide.
Heart Disease Prediction (HDP) is a difficult task as it needs advanced knowledge with …

Abstract Background and Purpose Chronic heart failure, a progressive disease with limited
treatment options currently available, especially in heart failure with preserved ejection …

Novel cardiac troponin activators were identified using a high throughput cardiac myofibril
ATPase assay and confirmed using a series of biochemical and biophysical assays. HTS hit …

Abstract Background and Aims In patients with chronic heart failure (HF), the MONITOR-HF
trial demonstrated the efficacy of pulmonary artery (PA)-guided HF therapy over standard of …

Background Natriuretic peptide (NP) testing is recommended for patients presenting to
primary care with symptoms of chronic heart failure (HF) to prioritise referral for diagnosis …

The prevalence of heart failure has increased in many developed countries including Japan
and the USA, due in large part to the aging of their populations. The lifetime risk of heart …

End stage heart failure is a terminal disease, and the only curative therapy is orthotopic
heart transplantation. Due to limited organ availability, alternative strategies have received …

Abstract Purpose of Review Heart failure with preserved ejection fraction (HFpEF) imposes a
significant burden on society and healthcare. The lack in efficacious therapies is likely due to …

Heart failure (HF) poses a significant economic burden in the US, with costs projected to
reach $70 billion by 2030. Cost-effectiveness analyses play a pivotal role in assessing the …